Angle PLC Announces Agreement with Recursion Pharmaceuticals
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) has signed an agreement with Recursion Pharmaceuticals for a pilot study using ANGLE's Parsortix CTC analysis. The study is fully funded, with potential for larger follow-on contracts if successful. This marks ANGLE's fourth pharma agreement in 2024, expanding its large pharma services business. Recursion, a clinical-stage TechBio company, has partnerships with multiple leading large pharma companies. While the initial study is modest in size, it could lead to significant opportunities. The agreement's details remain confidential between the parties.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) ha firmato un accordo con Recursion Pharmaceuticals per uno studio pilota che utilizza l'analisi CTC Parsortix di ANGLE. Lo studio è completamente finanziato, con potenziale per contratti successivi più ampi se avrà successo. Questo segna il quarto accordo farmacologico di ANGLE nel 2024, espandendo la sua attività di servizi per le grandi case farmaceutiche. Recursion, una azienda TechBio nella fase clinica, ha collaborazioni con numerose importanti compagnie farmaceutiche. Sebbene lo studio iniziale sia modesto in dimensioni, potrebbe portare a opportunità significative. I dettagli dell'accordo rimangono riservati tra le parti.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) ha firmado un acuerdo con Recursion Pharmaceuticals para un estudio piloto utilizando el análisis CTC Parsortix de ANGLE. El estudio está completamente financiado, con potencial para contratos de seguimiento más grandes si tiene éxito. Esto marca el cuarto acuerdo farmacéutico de ANGLE en 2024, ampliando su negocio de servicios a grandes farmacéuticas. Recursion, una empresa TechBio en etapa clínica, tiene asociaciones con múltiples compañías farmacéuticas líderes. Aunque el estudio inicial es modesto en tamaño, podría generar oportunidades significativas. Los detalles del acuerdo permanecen confidenciales entre las partes.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY)는 Recursion Pharmaceuticals와 ANGLE의 Parsortix CTC 분석을 사용하는 파일럿 연구에 대한 협약을 체결했습니다. 이 연구는 전액 자금 지원을 받으며, 성공할 경우 더 큰 후속 계약으로 이어질 가능성이 있습니다. 이는 ANGLE의 2024년 네 번째 제약 계약으로, 대형 제약 서비스 비즈니스를 확대하는 것입니다. Recursion은 여러 유수 대형 제약 회사와 파트너십을 맺고 있는 임상 단계의 TechBio 회사입니다. 초기 연구의 규모는 작지만 상당한 기회를 창출할 수 있습니다. 협약의 세부 사항은 당사자 간에 기밀로 유지됩니다.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) a signé un accord avec Recursion Pharmaceuticals pour une étude pilote utilisant l'analyse CTC Parsortix d'ANGLE. L'étude est entièrement financée, avec un potentiel pour de plus gros contrats de suivi si elle réussit. Cela marque le quatrième accord pharmaceutique d'ANGLE en 2024, élargissant ses services aux grandes entreprises pharmaceutiques. Recursion, une entreprise TechBio en phase clinique, a des partenariats avec plusieurs grandes sociétés pharmaceutiques. Bien que l'étude initiale soit modeste en taille, elle pourrait ouvrir la voie à des opportunités significatives. Les détails de l'accord restent confidentiels entre les parties.
ANGLE plc (AIM:AGL)(OTCQX:ANPCY) hat eine Vereinbarung mit Recursion Pharmaceuticals für eine Pilotstudie unter Verwendung von ANGLEs Parsortix CTC-Analyse unterzeichnet. Die Studie wird vollständig finanziert, mit Potenzial für größere Folgeverträge, wenn sie erfolgreich ist. Dies markiert das vierte Pharmaabkommen von ANGLE im Jahr 2024, wodurch das Geschäft mit großen Pharma-Dienstleistungen erweitert wird. Recursion, ein Unternehmen in der klinischen Phase der TechBio, hat Partnerschaften mit mehreren führenden großen Pharmaunternehmen. Obwohl die anfängliche Studie bescheiden im Umfang ist, könnte sie zu erheblichen Möglichkeiten führen. Die Details der Vereinbarung bleiben zwischen den Parteien vertraulich.
- Signed agreement with Recursion Pharmaceuticals for a pilot study
- Fully funded pilot study with potential for larger follow-on contracts
- Fourth pharma agreement in 2024, expanding large pharma services business
- Potential for significant opportunities if pilot study is successful
- Initial study is modest in size
New pharma agreement for Parsortix CTC analysis
GUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that it has signed an agreement with Recursion Pharmaceuticals, Inc. ("Recursion"), a leading clinical stage TechBio company decoding biology to radically improve lives.
The agreement is being initiated with a fully funded pilot study. Further details of the agreement are confidential between the parties.
ANGLE Chief Executive, Andrew Newland, commented:
"Whilst the study is modest in size during the pilot phase, there is the potential for larger follow-on contracts in the event of a successful pilot study. Recursion has partnerships with multiple leading large pharma companies and this agreement, ANGLE's fourth for 2024, further builds on the expansion of our large pharma services business."
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Andrew Newland, Chief Executive |
|
Berenberg (NOMAD and Broker) | +44 (0) 20 3207 7800 |
FTI Consulting |
|
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma.
Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on accesswire.com
FAQ
What is the new agreement ANGLE plc (ANPCY) has announced?
How many pharma agreements has ANGLE plc (ANPCY) secured in 2024?
What is the potential outcome of the pilot study for ANGLE plc (ANPCY)?
Who is Recursion Pharmaceuticals and why is this agreement significant for ANGLE plc (ANPCY)?
